Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Cristina Figueroa Magalhães has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and safety of palbociclib in older women with advanced HR-Positive/HER2-negative breast cancer: a systematic review and meta-analysis

    by Francisco Cezar Aquino de Moraes, Larissa Emi Tanimoto, Felipe Alves de Paiva, Barbara Antonia Dups Talah, Helen Cristina Beckert, Brando S. Becerra-Galindo, Maria Cristina Figueroa Magalhães

    Breast cancer (BC) is the most common cancer among women worldwide, with more than 3 million new cases and 1 million deaths projected by 2040 [1,2]. In the United States, it is the most frequently ...

  • Open Access

    Body Weight Status and Its Association With Patient‐Reported Outcomes in Women With Non‐Metastatic ER ‐Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy

    by Danielle Laperche‐Santos, Amanda Guimarães Castro Custodio, Fernanda Cesar Moura, Sulene Cunha Sousa Oliveira, Andrea Kazumi Shimada, Renata Arakelian, Heloisa Resende, Anna Luiza Zapalowski Galvão, Bruno Santos Wance de Souza, Monalisa Ceciliana Freitas Moreira de Andrade, et al.

    Purpose: To examine associations of body mass index (BMI) with sociodemographic, clinical, treatment‐related, psychosocial, and patient‐reported outcomes among women with non‐metastatic estrogen receptor‐positive (ER+) breast cancer receiving adjuvant endocrine therapy. Methods: This multicenter cross‐sectional study included 557 women treated at 11 Brazilian public and private institutions from June 2021 to March 2024. Participants were classified as having normal weight, overweight, or obesity. Health‐related quality of life was assessed using the EORTC QLQ‐C30 and QLQ‐BR23. Characteristics were compared across BMI categories using chi‐square or Fisher's exact test and Kruskal–Wallis test. Multinomial logistic regression examined factors associated with BMI category, using normal weight as the reference. Results: Of 557 participants, 172 had normal weight, 234 were overweight, and 151 had obesity. Education, comorbidities, hospital type, cancer stage, endocrine therapy, axillary dissection, prior chemotherapy, and radiotherapy differed across BMI categories. Participants with obesity had poorer physical functioning and greater pain. In the final model ( n = 554), axillary dissection (OR = 2.51; 95% CI = 1.37–4.59) and continuous medication use (OR = 2.92; 95% CI = 1.78–4.79) were associated with obesity versus normal weight. Tamoxifen was inversely associated with overweight (OR = 0.58; 95% CI = 0.36–0.91), whereas low treatment adherence (OR = 1.54; 95% CI = 1.01–2.35) and continuous medication use (OR = 1.68; 95% CI = 1.10–2.58) were positively associated. Conclusion: Overweight and obesity were common and associated with sociodemographic, clinical, treatment‐related, and selected quality‐of‐life characteristics. These findings support integrated survivorship care addressing weight‐related health, comorbidities, functional limitations, and symptom burden. Longitudinal studies are needed to clarify temporal relationships.

  • Open Access

    Genomic profiling by circulating tumor DNA in patients with hormone receptor-positive/HER2-negative advanced breast cancer: Prevalence of actionable mutations across treatment lines

    by Rodrigo Dienstmann, Márcio Luiz Martins Júnior, Breno Jeha Araújo, Cristiano Augusto Andrade de Resende, Rafael Duarte Paes, Christopher Lucas Negrete, Leandro Moreno Silveira da Silva, Daniela Jessica Pereira, Gustavo de Oliveira Bretas, Larissa Muller Gomes, et al.

  • Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis

    by Pedro Henrique de Souza Wagner, Gustavo Tadeu Freitas Uchôa Matheus, Danilo Monteiro Ribeiro, Maria Cristina Figueroa Magalhães, Francisco Cezar Aquino de Moraes

    Background BRCA1 and BRCA2 are tumor suppressor genes essential for DNA repair. Mutations in these genes significantly increase breast (BC) and ovarian cancer (OC) risk, with BRCA1-positive facing a 70% BC and 40% OC lifetime risk. While guidelines for BRCA-positive are well established, recommendations for BC surveillance in BRCA-patients already diagnosed with OC remain limited. This meta-analysis evaluates BC risk post-OC in BRCA-mutated women. Methods A systematic search of PubMed, Embase, and the Cochrane Library was performed. Single-arm outcomes were pooled using meta-analysis of proportions, and survival data were synthesized using hazard ratio (HR), both with 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic. All analyses were conducted in R (version 4.3.2). Results A total of 2380 patients from 10 retrospective cohort studies were included. Among them, 181 (8%; 95% CI: 6%–11%) developed BC post-OC, with similar rates observed for BRCA1 and BRCA2-mutated (9%; 95% CI: 7%–12%). In overall survival analysis, BRCA-mutated patients who developed BC after OC had significantly improved outcomes compared to those with OC only (HR = 0.4657; P < 0.001). Conclusion This meta-analysis underscores the need for tailored BC surveillance and evidence-based screening guidelines in BRCA-mutated OC survivors.


  • Effects of AKT Inhibitors for PIK3CA/AKT1/PTEN-Altered Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

    by Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Caroline R M Pereira, Estella Aparecida de Laia, Carlos Stecca, Maria Cristina Figueroa Magalhães, Paolo Tarantino


  • Open Access

    Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis

    by Francisco Cezar Aquino de Moraes, Caio Henrique Duarte de Castro Ribeiro, Felipe Dircêu Dantas Leite Pessôa, Juliana Ramos Chaves, Ana Paula Borges de Souza, Diego Di Felipe Ávila Alcantara, Margareth Maria Braun Guimarães Imbiriba, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano

    Currently, the primary methods for detecting HER2 expression levels are immunohistochemistry (IHC) and in situ hybridization (ISH), with the traditional standard being a HER2-positive score of 3 + accompanied by ERBB2 gene amplification detected through ISH. However, a new entity has recently emerged: HER2-low, defined as HER2 IHC 1 + or 2 + with negative ISH. HER2-low breast cancer, representing 45–60% of all HER2-negative tumors, has distinct biological characteristics and uncertain responses to conventional HER2-targeted therapies. Recent studies suggest varied clinical outcomes, highlighting the need for further investigation into the impact of HER2-low status on treatment efficacy and prognosis. This meta-analysis evaluates the difference in complete pathological response (pCR), disease-free survival (DFS), and overall survival (OS) between HER2-low and HER2-zero phenotypes. We systematically searched the main databases PubMed, Scopus, and Web of Science for articles evaluating women in neoadjuvant therapy expressing HER2-low and HER2-zero. We computed odds ratios (ORs) or hazard ratios (HRs) using DerSimonian and Laird random-effect models for all endpoints, with 95% confidence intervals (CIs). We assessed the heterogeneity using I2 statistics. R, version 4.2.3, was used for statistical analyses. 38 studies totaling 70,104 patients were included. The HER2-low group accounted for 61.3% of patients while HR + status represented 52.4% in the whole research. In 67,839 women, the pCR was analyzed, which in the overall cohort analysis favored the HER2-zero group (OR 0.84; 95% CI 0.78–0.90; p = 0.000005; I2 = 15%). Subgroup analyses for triple-negative breast cancer (TNBC) and HR + patients also favored HER2-zero expression, with an OR of 0.91 (95% CI 0.83–1.0; p < 0.041; I2 = 12%) and 0.75 (95% CI 0.70–0.81; p < 0.000001; I2 = 0%), respectively. In the multivariate analysis across all patients, both DFS and OS outcomes were significantly favorable for the HER2-low expression group, with HR 0.8317 (95% CI 0.7036–0.9832; p = 0.031) for DFS and HR 0.806 (95% CI 0.663–0.979; p = 0.03) for OS. Based on our findings, HER2-zero status is associated with a significantly higher pathological complete response (pCR) rate compared to HER2-low in early-stage breast cancer, and other survival outcomes. These results suggest that HER2-zero should be considered a prognostic factor in early-stage breast cancer and taken into account in neoadjuvant treatment planning and future clinical research.


  • Open Access

    Cuidados paliativos no ensino médico

    by Maria Cristina Figueroa Magalhães, Isadora Roberto Mesadri, Giulia Karolina Sotem Pandini, Fabiana Luiza Hornung, Gabrielle Previdi Patino, Rafaela Sartori Tonin, Juliana Gebara, Carolina Ragonetti, Ana Carolina Falzoni Pontello

    Objetivo: Avaliar conhecimento e preparo em Cuidados Paliativos de acadêmicos de Medicina. Metodologia: Estudo transversal, descritivo, de caráter epidemiológico, incluindo ao todo 201 estudantes, matriculados entre o primeiro ao sexto ano da graduação do curso de Medicina, em uma das 5 universidades de Curitiba/PR, com 15 questões subjetivas e objetivas retiradas de provas de concurso/residência, realizado após aprovação do Comitê de Ética em Pesquisa da Pontifícia Universidade Católica do Paraná (PUCPR), no período de setembro de 2020 a março de 2021. Aproximadamente 78,3% dos 201 estudantes avaliados não tiveram a disciplina no momento da avaliação ou não terão na graduação e apenas 17,9% qualificam-se a prestar Cuidados Paliativos. Entre aqueles que já cursaram ou estavam cursando a matéria, 36,4% consideraram-se aptos, enquanto dentre os que não cursaram, 87,3% negaram sentir-se habilitados. Resultados: Nas perguntas objetivas, a média de acertos dos alunos que já tiveram ou estavam cursando a matéria foi de 6,3/8 e do outro grupo, 5,4/8. Conclusão: Apesar dos estudantes possuírem bom conhecimento técnico em Cuidados Paliativos, sentem-se despreparados para o exercício.

  • Retracted

    RETRACTED: Omitting axillary lymph node dissection is associated with an increased risk of regional recurrence in early stage breast cancer: a systematic review and meta-analysis of randomized clinical trials

    by Jorge Henrique Cavalcanti Orestes Cardoso, Isabella Christina Amaral de Lara, Luis Eduardo Rodrigues Sobreira, Artur de Oliveira Macena Lôbo, Iasmin Isabelli Luiz Silvério, Maria Eduarda Cavalcanti Souza, Francisco Cezar Aquino de Moraes, Maria Cristina Figueroa Magalhães


  • Open Access

    Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials

    by Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N. Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães, et al.

    Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for advanced breast cancer combined with endocrine therapy (ET). The efficacy of CDK4/6 inhibitors plus ET in hormone estrogen-positive, human epidermal growth factor 2-negative (HR+/HER2−) early-stage breast cancer (esBC) is still to be confirmed. Methods: We performed a systematic review and a meta-analysis to investigate the efficacy of CDK4/6i plus ET in esBC. Main outcomes included invasive disease-free survival (iDFS), distant relapse-free survival (DRFS), and overall survival (OS). We included only phase III randomized controlled trials. We used RStudio version 4.2.3, and we considered p < 0.05 to be statistically significant. Results: Four studies were selected, including 14,168 patients, of which 7089 were treated with CDK4/6i plus ET and 7079 received ET monotherapy. Regarding patient characteristics, 6828 (48.2%) were premenopausal. Compared with ET alone, iDFS rates (HR 0.81; 95% CI: 0.67, 0.98; p = 0.034) were significantly in favor of CDK4/6 inhibitors plus ET. However, there were no significant differences in DRFS (HR 0.79; 95% CI: 0.58, 1.07; p = 0.132) nor OS (HR 0.96; 95% CI: 0.69, 1.35; p = 0.829). Conclusions: Our results show that the addition of CDK4/6 inhibitors is associated with a significant benefit for HR+/HER2− esBC patients in iDFS. More studies and longer follow-up are needed to assess overall survival benefits.


  • Open Access

    Bilateral Gonadal Dysgerminoma in a Phenotypic Female With 46,XY Disorder of Sexual Development: A Case Report

    by Ricardo Pasquini Neto, Maria Letícia Carnielli Tebet, Ohana Ivanski Dória de Vasconcelos, Mariana Faucz Munhoz da Cunha, Maria Cristina Figueroa Magalhães

    The 46,XY disorder of sexual development (DSD) is a rare congenital condition characterized by a 46,XY karyotype associated with complete or disturbed female gonadal development and a non-virilized phenotype. The presence of Y chromosome material in these patients' karyotypes increases the risk of germ cell tumor development. The present study reports a unique case of a 16-year-old phenotypically female patient presenting with primary amenorrhea, who was later diagnosed with 46,XY DSD. After bilateral salpingo-oophorectomy, the patient was diagnosed with stage IIIC dysgerminoma. The patient received four cycles of chemotherapy and showed a good response. The patient is currently alive and well, with no evidence of disease after the residual lymph node resection.